Skip to main content
. 2005 Nov;54(11):1553–1557. doi: 10.1136/gut.2005.065888

Figure 1.

Figure 1

 CpG DNA dose finding and specificity studies. (A) Peripheral blood mononuclear cells (PBMCs) from n = 2 healthy control individuals (hc1, hc2) were stimulated with M362 CpG DNA 0.1–10 μg/ml and with lipopolysaccharide (LPS 1 ng/ml; positive control), and tumour necrosis factor α (TNF) measured by enzyme linked immunosorbent assay (ELISA). (B) PBMCs from n = 6 healthy control individuals were stimulated with M362 CpG DNA or with control M362C DNA at 10 μg/ml and TNF measured by ELISA.